Atovaquone Therapeutic Drug Monitoring and Real-Time Sequencing in Breakthrough Pneumocystis Jirovecii Pneumonia: A Case Study of Personalized Medicine (ATC 2026) - Jun 17, 2026 - Abstract #Abstract C295; Pres time: Jun 22, 2026; 02:45 PM - 03:45 PM; Location: Exhibit Hall; "The patient was receiving ruxolitinib with tapered prednisone and prophylaxis with letermovir, acyclovir, posaconazole, and atovaquone (1.5 g daily), taken without food...Oral trimethoprim-sulfamethoxazole was initiated but discontinued due to vomiting, kidney injury and hyperkalemia.* Atovaquone serum level while on daily prophylaxis was subtherapeutic (6 mg/L)... PJP is challenging to manage, largely due to treatment toxicities. This case highlights the importance of individualized, "precision medicine" approaches, such as atovaquone TDM and pathogen gene sequencing from BAL in select cases."
Case study • Clinical • Cough • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Pneumonia • Pulmonary Disease • Respiratory Diseases
|
|
S. Panaccione 1; X. Zhou 1; T. Hong 1; S. Papadimatos 2; A. Tziotis 2; D. Farmakiotis 2
|